Effect of telmisartan on vascular endothelium in hypertensive and type 2 diabetic hypertensive patients;Hipertansif ve tip 2 diabetik hipertansif olgularda telmisartanin damar endoteli üzerine etkisi

Turkish Journal of Medical Sciences

Volumn 40, Issue 2, 2010, Pages 239-248

  Barutçuoglu, Burcu ^a   Parildar, Zuhal ^a   Mutaf, M Işil ^a   Özmen, Dilek ^a   Alioǧlu, Emin ^a   Habif, Sara ^a   Bayindir, Oya ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Endothelial dysfunction; Essential hypertension; Type 2 diabetes mellitus

Indexed keywords

BRACHIAL ARTERY; CARDIO-VASCULAR DISEASE; CONTROL SUBJECT; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FLOW MEDIATED DILATION; GROUP 4; HYPERTENSIVE PATIENTS; PLASMINOGEN ACTIVATOR INHIBITOR-1; PLATELET ENDOTHELIAL CELL ADHESION MOLECULES; TELMISARTAN; THROMBOMODULIN; TYPE 2 DIABETES MELLITUS; VASCULAR CELL ADHESION MOLECULE-1; VASCULAR ENDOTHELIUM;

ADHESION; BIOMOLECULES; BLOOD PRESSURE; BODY FLUIDS; CELL ADHESION; ENDOTHELIAL CELLS; MEDICAL PROBLEMS;

SELF ASSEMBLY;

ALBUMIN; ARYLDIALKYLPHOSPHATASE; CD31 ANTIGEN; NITRATE; ORAL ANTIDIABETIC AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; TELMISARTAN; THROMBOMODULIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BLOOD PRESSURE REGULATION; BRONCHIAL ARTERY; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 77952466532     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: 10.3906/sag-0807-11     Document Type: Article

References (39)

1. Müller MM, Griesmacher A. Markers of endothelial dysfunction. Clin Chem Lab Med 2000; 38: 77-85.
2. Mombouli JV, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
3. Schmidt-Ott KM, Kagiyama S, Phillips MI. The multiple actions of angiotensin II in atherosclerosis. Regul Pept 2000; 93: 65-77.
4. McClellan KJ, Markham A. Telmisartan. Drugs 1998; 5: 1039-46.
5. Sierra C, Ruilope LM. New-onset diabetes and antihypertensive therapy: comment on ALLHAT trial. J Renin Angiotensin Aldosterone Syst 2003; 4: 169-70.
6. Vitale C, Mercuro G, Castiglioni C, et al. Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovascular Diabetology 2005; 4: 6-14.
7. Bories PN, Bories C. Nitrate determination in biological fluids by an enzymatic one step assay with nitrate reductase. Clin Chem 1995; 41: 904-07.
8. Mueller RF, Hornung S, Furlong CE, Anderson J, Giblett ER, Motulsky AG. Plasma Paraoxonase polymorphism: A new enzyme assay, population, family, biochemical and linkage studies. Am J Hum Genet 1983; 35: 393-408.
9. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
10. Mackness MI, Durrington PN, Mackness B. How high-density lipoprotein protects against the effects of lipid peroxidation. Curr Opin Lipidol 2000; 11: 383-88.
11. Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G et al. PON-1 L55 M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 2002; 32: 9-15.
12. Rice GI, Ossei-Gerning Ni, Stickland MH, Grant PJ. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease. Coron Artery Dis 1997; 8: 677-82.
13. Abbott CA, Mackness MI, Kumar S, Boulton AJ, Durrington PN. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler Thromb Vasc Biol 1995; 15: 1812-18.
14. Gowri MS, Van der Westhuyzen DR, Bridges SR, Anderson JW. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 1999; 19: 2226-33.
15. Rahmani M, Raiszadeh F, Allahverian S, Kiaii S, Navab M, Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-1/B and serum concentration of apolipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atheroscler 2002; 162: 381-89.
16. Saisho Y, Komiya N, Hirose H. Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: blood pressureindependent effect of valsartan. Diabetes Res Clin Pract 2006; 74: 201-3.
17. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes, Obesity and Metab 2002; 4: 224-38.
18. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S et al. Different affect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-1286.
19. Pontrmoli R, Sofia A, Tirotta A, Ravera M, Nicotella C, Viazzi F. The deletion polymorphism of the angiotensin-1 converting enzyme gene is associated with target organ damage in essential hypertension. J Am Soc Nephrol 1996; 7: 2250-58.
20. Deckert T, Kofoed-Enevolsen A, Videl P, Norgaard K, Andreasen HB, Feldt-Rasmussen B. Size and charge selectivity in non-diabetic patients with and without albuminuria. Diabetologia 1993; 36: 244-51.
21. Yudkin JS. Hyperinsulinemia, insulin resistance, microalbuminuria and the risk of coronary heart disease. Ann Med 1996; 28: 433-38.
22. Vaughan DE. Angiotensin and vascular fibrinolytic balance. AJH 2002; 15: 3S-8S
23. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation 2000; 101: 264-69.
24. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H et al. Soluble Thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. Lancet 1999; 353: 1729-34.
25. Sadawa K. Naiki M, Yago H, Matsushita K, Ohtsuki T, Kitagawa K, et al. Hypertension associated with reduced plasma thrombomodulin levels and a hypercoagulable state in rats. Clin Exp Hypertens 2003; 25: 73-84.
26. DeSouza CA, Dengel DR, Macko FR, Cox K, Seale DR. Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension. Am J Hypertens 1997; 10: 1335-41.
27. Matsumoto K, Sera Y, Nakamura H, Ueki Y, Miyake S. Serum concentrations of soluble adhesion molecules are related to degree of hyperglycemia and insulin resistance in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 2002; 55: 131-38.
28. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B et al. For the LIFE study group. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-86.
29. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al; VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
30. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARMPreserved Trial. Lancet 2003; 362: 777-81.
31. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARMAlternative trial. Lancet 2003; 362: 772-76.
32. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensinconverting- enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-71.
33. K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B et al. Rationale, design, and baseline characteristics of two large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
34. Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 2008; 97: 418-31.
35. Pershadsingh HA, Kurtz TW. Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabetes Care 2004; 27: 1015.
36. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, doubleblind, placebo controlled 12-month study. Hypertens Res 2004; 27: 457-64.
37. AH. Preventing renal complications in diabetic patients: the Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study. Acta Diabetol. 2005; 42 Suppl 1: S42-9
38. Kulkarni RB, Kulkarni BN, Hariharan RS, Naikwadi A, Gawde A, Baliga V et al. A pilot study for evaluation of the efficacy and safety of telmisartan in reducing microalbuminuria in hypertensive patients with type 2 diabetes mellitus. J Indian Med Assoc. 2005; 103: 187-91.
39. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004; 24: 930-34.